Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Veracyte Inc
(NQ:
VCYT
)
32.00
+0.94 (+3.03%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Veracyte Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
New Data to be Presented at CHEST 2021 Showcase Clinical Performance of Veracyte’s Genomic Diagnostic Tests in Lung Cancer and Interstitial Lung Disease
October 06, 2021
From
Veracyte, Inc.
Via
Business Wire
Is Veracyte Still a Buy After Its Recent Rally?
October 05, 2021
Shares of the genetic diagnostics company are down nearly 50% from their 52-week high in February.
Via
The Motley Fool
Biotech Playbook Revisited As Technicals Weaken
September 27, 2021
Recent breakthroughs with mRNA vaccines over the past two years have shown the enormous potential for transformative therapies. DNA sequencing took off five years ago and new applications are still...
Via
Talk Markets
Veracyte Announces that New NCCN Guidelines Uniquely Recommend Use of Decipher Prostate Genomic Test Score to Guide Specific Treatment for Men Following Radical Prostatectomy
September 14, 2021
From
Veracyte, Inc.
Via
Business Wire
Where Veracyte Stands With Analysts
August 26, 2021
Over the past 3 months, 6 analysts have published their opinion on Veracyte (NASDAQ:
Via
Benzinga
What 9 Analyst Ratings Have To Say About Veracyte
July 30, 2021
Within the last quarter, Veracyte (NASDAQ:VCYT) has observed the following...
Via
Benzinga
The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs
September 15, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 14) Alcon Inc. (NYSE: ALC)...
Via
Benzinga
Exposures
COVID-19
Small Cap Biotechs Sagging But More Deals Are Likely to Perk Up the Market
September 09, 2021
Despite record highs in the Nasdaq recently at the 15,000 level the biotech market seems sluggish. Speculation has ebbed. As if we need a green screen every day.
Via
Talk Markets
Earnings Scheduled For July 29, 2021
July 29, 2021
Companies Reporting Before The Bell • Smith & Nephew (NYSE:SNN) is projected to report earnings for its second quarter. • Cohen & Co (AMEX:COHN) is...
Via
Benzinga
Expert Ratings For Veracyte
June 28, 2021
Within the last quarter, Veracyte (NASDAQ:VCYT) has observ...
Via
Benzinga
Veracyte Further Strengthens Medical Team with Appointment of Joshua Klopper, M.D., as Medical Director of Endocrinology
September 01, 2021
From
Veracyte, Inc.
Via
Business Wire
Veracyte to Participate in Morgan Stanley 19th Annual Global Healthcare Conference
August 31, 2021
From
Veracyte, Inc.
Via
Business Wire
Vaccine Victory
August 24, 2021
Monday the US stock market moved into further robust mode fueled by official FDA approval of the Pfizer and BioNTech COVID-19 vaccines. Will the momentum last through to Thursday when the Fed's Jackson...
Via
Talk Markets
Topics
Economy
Exposures
COVID-19
Interest Rates
Product Safety
Veracyte Named a San Francisco Bay Area “Top Workplace” for Eighth Consecutive Year
August 23, 2021
From
Veracyte, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
August 20, 2021
Gainers CASI Pharmaceuticals (NASDAQ:CASI
Via
Benzinga
Veracyte Completes Acquisition of HalioDx
August 03, 2021
From
Veracyte
Via
Business Wire
12 Health Care Stocks Moving In Friday's Intraday Session
July 30, 2021
Gainers Erytech Pharma (NASDAQ:ERYP) sha...
Via
Benzinga
63 Biggest Movers From Friday
August 02, 2021
Gainers ERYTECH Pharma S.A. (NASDAQ: ERYP) shares surged 55% to close at $6.37 on Friday after the company said the FDA has granted its eryaspase fast track designation for the...
Via
Benzinga
Exposures
Product Safety
41 Stocks Moving In Friday's Mid-Day Session
July 30, 2021
Gainers ERYTECH Pharma S.A. (NASDAQ: ERYP) shares jumped 90.6% to $7.84 after the company said the FDA has granted its eryaspase fast track designation for the treatment of acute...
Via
Benzinga
Exposures
Product Safety
Veracyte Announces Second Quarter 2021 Financial Results
July 29, 2021
From
Veracyte, Inc.
Via
Business Wire
The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs
July 29, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) AbbVie Inc. (NYSE: ABBV)...
Via
Benzinga
Exposures
Product Safety
After Naming a New CFO, Is This Genetic Diagnostics Company a Buy?
July 29, 2021
Veracyte appointed Rebecca Chambers, who boasts a wealth of financial executive experience, to the position.
Via
The Motley Fool
New Study Suggests Decipher Prostate Biopsy Test May Help Guide Use of Active Surveillance in Prostate Cancer
July 27, 2021
From
Veracyte, Inc.
Via
Business Wire
Veracyte Appoints Rebecca Chambers as Executive Vice President and Chief Financial Officer, Further Positioning Company for Global Growth
July 12, 2021
From
Veracyte, Inc.
Via
Business Wire
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More
July 25, 2021
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start...
Via
Benzinga
Exposures
Product Safety
Veracyte to Release Second Quarter 2021 Financial Results on July 29, 2021
July 08, 2021
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces Key Appointments to Executive Leadership Team, Supporting Global Expansion
July 08, 2021
From
Veracyte, Inc.
Via
Business Wire
Mid-Cap Biotech Picks: Seasonal Rally Underway
July 03, 2021
Many Mid-Cap biotech stocks were hit hard after the February peak. We suggest three new mid-cap biotech picks. All three picks can be volatile but very tradable.
Via
Talk Markets
Veracyte Announces Two Pre-Eminent Physician Appointments, Further Strengthening Medical Team
July 01, 2021
From
Veracyte, Inc.
Via
Business Wire
Looking Into Veracyte's Return On Capital Employed
June 25, 2021
During Q1, Veracyte's (NASDAQ:VCYT) reported sales totaled $36.70 million. Despite a 462.62% in earnings, the company posted a loss of $45.41 million. Veracyte collected $34.54...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.